{
  "DOI": "10.1186/s40246-023-00506-3",
  "ISSN": [
    "1479-7364"
  ],
  "URL": "http://dx.doi.org/10.1186/s40246-023-00506-3",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eBackground\u003c/jats:title\u003e\n                \u003cjats:p\u003eThe influence of genetic factors on the pharmacokinetics and clinical outcomes of rivaroxaban in patients with non-valvular atrial fibrillation (NVAF) is poorly understood. This study aimed to explore the effects of \u003cjats:italic\u003eCYP3A4/5\u003c/jats:italic\u003e, \u003cjats:italic\u003eABCB1\u003c/jats:italic\u003e, and \u003cjats:italic\u003eABCG2\u003c/jats:italic\u003e gene polymorphisms on the trough concentrations and the bleeding risk of rivaroxaban in NVAF patients.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003ePatients and methods\u003c/jats:title\u003e\n                \u003cjats:p\u003eThis study is a prospective multicenter study. The patient's blood samples were collected to detect the steady-state trough concentrations of rivaroxaban and gene polymorphisms. We visited the patients regularly at month 1, 3, 6, and 12 to record bleeding events and medications.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eResults\u003c/jats:title\u003e\n                \u003cjats:p\u003eA total of 95 patients were enrolled in this study, and 9 gene loci were detected. For the dose-adjusted trough concentration ratio (C\u003cjats:sub\u003etrough\u003c/jats:sub\u003e/D) of rivaroxaban, the homozygous mutant type was significantly lower than wild type at \u003cjats:italic\u003eABCB1\u003c/jats:italic\u003e rs4148738 locus (TT vs. CC, \u003cjats:italic\u003eP\u003c/jats:italic\u003e = 0.033), and the mutant type was significantly lower than the wild type at \u003cjats:italic\u003eABCB1\u003c/jats:italic\u003e rs4728709 locus (AA + GA vs. GG, \u003cjats:italic\u003eP\u003c/jats:italic\u003e = 0.008). \u003cjats:italic\u003eABCB1\u003c/jats:italic\u003e (rs1045642, rs1128503), \u003cjats:italic\u003eCYP3A4\u003c/jats:italic\u003e (rs2242480, rs4646437), \u003cjats:italic\u003eCYP3A5\u003c/jats:italic\u003e (rs776746), and \u003cjats:italic\u003eABCG2\u003c/jats:italic\u003e (rs2231137, rs2231142) gene polymorphisms had no significant effect on the C\u003cjats:sub\u003etrough\u003c/jats:sub\u003e/D of rivaroxaban. For the bleeding events, we found that there were no significant differences among genotypes of all gene loci.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eConclusion\u003c/jats:title\u003e\n                \u003cjats:p\u003eThis study found for the first time that \u003cjats:italic\u003eABCB1\u003c/jats:italic\u003e rs4148738 and rs4728709 gene polymorphisms had a significant impact on the C\u003cjats:sub\u003etrough\u003c/jats:sub\u003e/D of rivaroxaban in NVAF patients. \u003cjats:italic\u003eCYP3A4/5\u003c/jats:italic\u003e, \u003cjats:italic\u003eABCB1\u003c/jats:italic\u003e, and \u003cjats:italic\u003eABCG2\u003c/jats:italic\u003e gene polymorphisms were not associated with the bleeding risk of rivaroxaban.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e",
  "alternative-id": [
    "506"
  ],
  "article-number": "59",
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "17 December 2022"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 2,
      "value": "3 July 2023"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 3,
      "value": "7 July 2023"
    },
    {
      "group": {
        "label": "Declarations",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Ethics approval and consent to participate",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "The studies involving human participants were reviewed and approved by Fujian Medical University Union Hospital Ethics Committee (Number: 2018YF005-02, date: 2018-3-14). Informed consent was obtained from all individual participants included in the study."
    },
    {
      "group": {
        "label": "Competing interests",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 3,
      "value": "The authors declare that they have no competing interests."
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Wu",
      "given": "Tingting",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Wu",
      "given": "Shuyi",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Li",
      "given": "Li",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Xiang",
      "given": "Jing",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Wang",
      "given": "Na",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Chen",
      "given": "Wenjun",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Zhang",
      "given": "Jinhua",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Human Genomics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2023,
        7,
        7
      ]
    ],
    "date-time": "2023-07-07T10:01:38Z",
    "timestamp": 1688724098000
  },
  "deposited": {
    "date-parts": [
      [
        2023,
        7,
        7
      ]
    ],
    "date-time": "2023-07-07T10:06:33Z",
    "timestamp": 1688724393000
  },
  "indexed": {
    "date-parts": [
      [
        2024,
        4,
        16
      ]
    ],
    "date-time": "2024-04-16T09:49:48Z",
    "timestamp": 1713260988562
  },
  "is-referenced-by-count": 5,
  "issn-type": [
    {
      "type": "electronic",
      "value": "1479-7364"
    }
  ],
  "issue": "1",
  "issued": {
    "date-parts": [
      [
        2023,
        7,
        7
      ]
    ]
  },
  "journal-issue": {
    "issue": "1",
    "published-online": {
      "date-parts": [
        [
          2023,
          12
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2023,
            7,
            7
          ]
        ],
        "date-time": "2023-07-07T00:00:00Z",
        "timestamp": 1688688000000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2023,
            7,
            7
          ]
        ],
        "date-time": "2023-07-07T00:00:00Z",
        "timestamp": 1688688000000
      }
    }
  ],
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-023-00506-3.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1186/s40246-023-00506-3/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-023-00506-3.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "prefix": "10.1186",
  "published": {
    "date-parts": [
      [
        2023,
        7,
        7
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2023,
        7,
        7
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1111/j.1538-7836.2010.03759.x",
      "author": "H Bounameaux",
      "doi-asserted-by": "publisher",
      "first-page": "621",
      "issue": "4",
      "journal-title": "J Thromb Haemost",
      "key": "506_CR1",
      "unstructured": "Bounameaux H, Reber G. New oral antithrombotics: a need for laboratory monitoring. Against. J Thromb Haemost. 2010;8(4):621–6.",
      "volume": "8",
      "year": "2010"
    },
    {
      "DOI": "10.2146/ajhp160756",
      "author": "AA Alalwan",
      "doi-asserted-by": "publisher",
      "first-page": "1237",
      "issue": "16",
      "journal-title": "Am J Health Syst Pharm",
      "key": "506_CR2",
      "unstructured": "Alalwan AA, Voils SA, Hartzema AG. Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation. Am J Health Syst Pharm. 2017;74(16):1237–44.",
      "volume": "74",
      "year": "2017"
    },
    {
      "DOI": "10.1161/STROKEAHA.119.025824",
      "author": "P Blin",
      "doi-asserted-by": "publisher",
      "first-page": "2469",
      "issue": "9",
      "journal-title": "Stroke",
      "key": "506_CR3",
      "unstructured": "Blin P, Fauchier L, Dureau-Pournin C, et al. Effectiveness and safety of rivaroxaban 15 or 20 mg versus vitamin K antagonists in nonvalvular atrial fibrillation. Stroke. 2019;50(9):2469–76.",
      "volume": "50",
      "year": "2019"
    },
    {
      "DOI": "10.1056/NEJMoa1009638",
      "author": "MR Patel",
      "doi-asserted-by": "publisher",
      "first-page": "883",
      "issue": "10",
      "journal-title": "N Engl J Med",
      "key": "506_CR4",
      "unstructured": "Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.",
      "volume": "365",
      "year": "2011"
    },
    {
      "DOI": "10.1093/europace/euab065",
      "author": "J Steffel",
      "doi-asserted-by": "publisher",
      "first-page": "1612",
      "issue": "10",
      "journal-title": "Europace",
      "key": "506_CR5",
      "unstructured": "Steffel J, Collins R, Antz M, et al. 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–76.",
      "volume": "23",
      "year": "2021"
    },
    {
      "DOI": "10.1002/jcph.288",
      "author": "IG Girgis",
      "doi-asserted-by": "publisher",
      "first-page": "917",
      "issue": "8",
      "journal-title": "J Clin Pharmacol",
      "key": "506_CR6",
      "unstructured": "Girgis IG, Patel MR, Peters GR, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF. J Clin Pharmacol. 2014;54(8):917–27.",
      "volume": "54",
      "year": "2014"
    },
    {
      "DOI": "10.1111/j.1472-8206.2011.00981.x",
      "author": "R Kreutz",
      "doi-asserted-by": "publisher",
      "first-page": "27",
      "issue": "1",
      "journal-title": "Fundam Clin Pharmacol",
      "key": "506_CR7",
      "unstructured": "Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol. 2012;26(1):27–32.",
      "volume": "26",
      "year": "2012"
    },
    {
      "DOI": "10.1007/s40292-019-00342-4",
      "author": "D Sychev",
      "doi-asserted-by": "publisher",
      "first-page": "413",
      "issue": "5",
      "journal-title": "High Blood Press Cardiovasc Prev",
      "key": "506_CR8",
      "unstructured": "Sychev D, Minnigulov R, Bochkov P, et al. Effect of CYP3A4, CYP3A5, ABCB1 gene polymorphisms on rivaroxaban pharmacokinetics in patients undergoing total hip and knee replacement surgery. High Blood Press Cardiovasc Prev. 2019;26(5):413–20.",
      "volume": "26",
      "year": "2019"
    },
    {
      "DOI": "10.1124/jpet.111.180240",
      "author": "MJ Gnoth",
      "doi-asserted-by": "publisher",
      "first-page": "372",
      "issue": "1",
      "journal-title": "J Pharmacol Exp Ther",
      "key": "506_CR9",
      "unstructured": "Gnoth MJ, Buetehorn U, Muenster U, et al. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther. 2011;338(1):372–80.",
      "volume": "338",
      "year": "2011"
    },
    {
      "DOI": "10.1016/j.taap.2004.10.012",
      "author": "EM Leslie",
      "doi-asserted-by": "publisher",
      "first-page": "216",
      "issue": "3",
      "journal-title": "Toxicol Appl Pharmacol",
      "key": "506_CR10",
      "unstructured": "Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005;204(3):216–37.",
      "volume": "204",
      "year": "2005"
    },
    {
      "DOI": "10.1111/bcpt.12005",
      "author": "IY Gong",
      "doi-asserted-by": "publisher",
      "first-page": "164",
      "issue": "3",
      "journal-title": "Basic Clin Pharmacol Toxicol",
      "key": "506_CR11",
      "unstructured": "Gong IY, Mansell SE, Kim RB. Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry. Basic Clin Pharmacol Toxicol. 2013;112(3):164–70.",
      "volume": "112",
      "year": "2013"
    },
    {
      "DOI": "10.1016/j.gpb.2016.03.008",
      "author": "S Ahmed",
      "doi-asserted-by": "publisher",
      "first-page": "298",
      "issue": "5",
      "journal-title": "Genomics Proteomics Bioinform",
      "key": "506_CR12",
      "unstructured": "Ahmed S, Zhou Z, Zhou J, et al. Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genomics Proteomics Bioinform. 2016;14(5):298–313.",
      "volume": "14",
      "year": "2016"
    },
    {
      "DOI": "10.3390/jpm9010007",
      "author": "SH Kanuri",
      "doi-asserted-by": "publisher",
      "first-page": "7",
      "issue": "1",
      "journal-title": "J Pers Med",
      "key": "506_CR13",
      "unstructured": "Kanuri SH, Kreutz RP. Pharmacogenomics of novel direct oral anticoagulants: newly identified genes and genetic variants. J Pers Med. 2019;9(1):7.",
      "volume": "9",
      "year": "2019"
    },
    {
      "DOI": "10.1111/bcpt.13488",
      "author": "J Nakagawa",
      "doi-asserted-by": "publisher",
      "first-page": "297",
      "issue": "2",
      "journal-title": "Basic Clin Pharmacol Toxicol",
      "key": "506_CR14",
      "unstructured": "Nakagawa J, Kinjo T, Iizuka M, et al. Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation. Basic Clin Pharmacol Toxicol. 2021;128(2):297–304.",
      "volume": "128",
      "year": "2021"
    },
    {
      "DOI": "10.1007/s00228-019-02639-8",
      "author": "J Zdovc",
      "doi-asserted-by": "publisher",
      "first-page": "817",
      "issue": "6",
      "journal-title": "Eur J Clin Pharmacol",
      "key": "506_CR15",
      "unstructured": "Zdovc J, Petre M, Pišlar M, et al. Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of rivaroxaban: a population pharmacokinetic-pharmacodynamic study. Eur J Clin Pharmacol. 2019;75(6):817–24.",
      "volume": "75",
      "year": "2019"
    },
    {
      "author": "M Chen",
      "first-page": "724",
      "issue": "8",
      "journal-title": "J Clin Cardiol",
      "key": "506_CR16",
      "unstructured": "Chen M, Chen H, Ling WW, et al. Population pharmacokinetics of rivaroxaban in patients with nonvalvular atrial fibrillation. J Clin Cardiol. 2020;36(8):724–30.",
      "volume": "36",
      "year": "2020"
    },
    {
      "DOI": "10.3389/fphar.2021.639854",
      "author": "Y Wang",
      "doi-asserted-by": "publisher",
      "journal-title": "Front Pharmacol",
      "key": "506_CR17",
      "unstructured": "Wang Y, Chen M, Chen H, et al. Influence of ABCB1 gene polymorphism on rivaroxaban blood concentration and hemorrhagic events in patients with atrial fibrillation. Front Pharmacol. 2021;12: 639854.",
      "volume": "12",
      "year": "2021"
    },
    {
      "author": "TT Wu",
      "first-page": "120",
      "issue": "10",
      "journal-title": "Chin J Clin Pharmacol",
      "key": "506_CR18",
      "unstructured": "Wu TT, Xia XT, Fu JL, et al. Simultaneous concentration determination of dabigatran and rivaroxaban in human plasma by LC-MS/MS. Chin J Clin Pharmacol. 2019;35(10):120–3.",
      "volume": "35",
      "year": "2019"
    },
    {
      "DOI": "10.1111/j.1365-2125.2010.03753.x",
      "author": "D Kubitza",
      "doi-asserted-by": "publisher",
      "first-page": "703",
      "issue": "5",
      "journal-title": "Br J Clin Pharmacol",
      "key": "506_CR19",
      "unstructured": "Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2010;70(5):703–12.",
      "volume": "70",
      "year": "2010"
    },
    {
      "DOI": "10.1161/CIRCEP.121.007955",
      "author": "PL Mar",
      "doi-asserted-by": "publisher",
      "issue": "5",
      "journal-title": "Circ Arrhythm Electrophysiol",
      "key": "506_CR20",
      "unstructured": "Mar PL, Horbal P, Chung MK, et al. drug interactions affecting antiarrhythmic drug use. Circ Arrhythm Electrophysiol. 2022;15(5): e007955.",
      "volume": "15",
      "year": "2022"
    },
    {
      "DOI": "10.1007/s11239-020-02037-3",
      "author": "S Hanigan",
      "doi-asserted-by": "publisher",
      "first-page": "636",
      "issue": "4",
      "journal-title": "J Thromb Thrombolysis",
      "key": "506_CR21",
      "unstructured": "Hanigan S, Das J, Pogue K, et al. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis. 2020;49(4):636–43.",
      "volume": "49",
      "year": "2020"
    },
    {
      "DOI": "10.1089/gtmb.2017.0152",
      "author": "DA Sychev",
      "doi-asserted-by": "publisher",
      "first-page": "51",
      "issue": "1",
      "journal-title": "Genet Test Mol Biomarkers",
      "key": "506_CR22",
      "unstructured": "Sychev DA, Vardanyan A, Rozhkov A, et al. CYP3A activity and rivaroxaban serum concentrations in Russian patients with deep vein thrombosis. Genet Test Mol Biomarkers. 2018;22(1):51–4.",
      "volume": "22",
      "year": "2018"
    },
    {
      "author": "K Ing Lorenzini",
      "first-page": "494",
      "issue": "7",
      "journal-title": "Front Pharmacol",
      "key": "506_CR23",
      "unstructured": "Ing Lorenzini K, Daali Y, Fontana P, et al. Rivaroxaban-induced hemorrhage associated with ABCB1 genetic defect. Front Pharmacol. 2016;19(7):494.",
      "volume": "19",
      "year": "2016"
    },
    {
      "DOI": "10.1016/j.thromres.2016.05.025",
      "author": "C Dimatteo",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "Thromb Res",
      "key": "506_CR24",
      "unstructured": "Dimatteo C, D’Andrea G, Vecchione G, et al. Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res. 2016;144:1–5.",
      "volume": "144",
      "year": "2016"
    },
    {
      "DOI": "10.1038/s41598-018-28622-4",
      "author": "AL Sennesael",
      "doi-asserted-by": "publisher",
      "first-page": "10514",
      "issue": "1",
      "journal-title": "Sci Rep",
      "key": "506_CR25",
      "unstructured": "Sennesael AL, Panin N, Vancraeynest C, et al. Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines. Sci Rep. 2018;8(1):10514.",
      "volume": "8",
      "year": "2018"
    },
    {
      "DOI": "10.1002/cpt.2316",
      "author": "J Lähteenmäki",
      "doi-asserted-by": "publisher",
      "first-page": "768",
      "issue": "3",
      "journal-title": "Clin Pharmacol Ther",
      "key": "506_CR26",
      "unstructured": "Lähteenmäki J, Vuorinen AL, Pajula J, et al. Pharmacogenetics of bleeding and thromboembolic events in direct oral anticoagulant users. Clin Pharmacol Ther. 2021;110(3):768–76.",
      "volume": "110",
      "year": "2021"
    },
    {
      "DOI": "10.1182/blood-2012-07-440107",
      "author": "JJ Yang",
      "doi-asserted-by": "publisher",
      "first-page": "4197",
      "issue": "20",
      "journal-title": "Blood",
      "key": "506_CR27",
      "unstructured": "Yang JJ, Cheng C, Devidas M, et al. Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood. 2012;120(20):4197–204.",
      "volume": "120",
      "year": "2012"
    },
    {
      "DOI": "10.1007/s00280-017-3268-y",
      "author": "M Tandia",
      "doi-asserted-by": "publisher",
      "first-page": "759",
      "issue": "4",
      "journal-title": "Cancer Chemother Pharmacol",
      "key": "506_CR28",
      "unstructured": "Tandia M, Mhiri A, Paule B, et al. Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study. Cancer Chemother Pharmacol. 2017;79(4):759–66.",
      "volume": "79",
      "year": "2017"
    },
    {
      "DOI": "10.1161/CIRCGENETICS.113.000099",
      "author": "MK DeGorter",
      "doi-asserted-by": "publisher",
      "first-page": "400",
      "issue": "4",
      "journal-title": "Circ Cardiovasc Genet",
      "key": "506_CR29",
      "unstructured": "DeGorter MK, Tirona RG, Schwarz UI, et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet. 2013;6(4):400–8.",
      "volume": "6",
      "year": "2013"
    },
    {
      "DOI": "10.1007/s10637-014-0178-2",
      "author": "C Narjoz",
      "doi-asserted-by": "publisher",
      "first-page": "257",
      "issue": "1",
      "journal-title": "Invest New Drugs",
      "key": "506_CR30",
      "unstructured": "Narjoz C, Cessot A, Thomas-Schoemann A, et al. Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. Invest New Drugs. 2015;33(1):257–68.",
      "volume": "33",
      "year": "2015"
    }
  ],
  "reference-count": 30,
  "references-count": 30,
  "resource": {
    "primary": {
      "URL": "https://humgenomics.biomedcentral.com/articles/10.1186/s40246-023-00506-3"
    }
  },
  "score": 0,
  "short-container-title": [
    "Hum Genomics"
  ],
  "source": "Crossref",
  "title": [
    "The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "17"
}